9.08
price up icon0.00%   0.00
after-market Handel nachbörslich: 9.25 0.17 +1.87%
loading
Schlusskurs vom Vortag:
$9.08
Offen:
$9.06
24-Stunden-Volumen:
1.47M
Relative Volume:
1.04
Marktkapitalisierung:
$437.72M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-1.0822
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
-1.84%
1M Leistung:
+37.16%
6M Leistung:
+57.09%
1J Leistung:
-16.08%
1-Tages-Spanne:
Value
$9.06
$9.17
1-Wochen-Bereich:
Value
$9.04
$9.295
52-Wochen-Spanne:
Value
$4.62
$13.47

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
Firmenname
Sage Therapeutics Inc
Name
Telefon
617-299-8380
Name
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Mitarbeiter
487
Name
Twitter
@SageBiotech
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
SAGE's Discussions on Twitter

Vergleichen Sie SAGE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SAGE
Sage Therapeutics Inc
9.08 437.72M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-11 Fortgesetzt BofA Securities Underperform
2024-11-21 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-10-04 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-07-30 Herabstufung TD Cowen Buy → Hold
2024-07-25 Herabstufung JP Morgan Overweight → Neutral
2024-05-29 Eingeleitet Citigroup Sell
2024-05-29 Eingeleitet Robert W. Baird Neutral
2024-04-17 Herabstufung BofA Securities Neutral → Underperform
2023-12-12 Eingeleitet Deutsche Bank Hold
2023-08-08 Herabstufung Canaccord Genuity Buy → Hold
2023-08-08 Herabstufung Goldman Buy → Neutral
2023-08-08 Herabstufung Needham Buy → Hold
2023-08-07 Herabstufung BofA Securities Buy → Neutral
2023-08-07 Herabstufung Oppenheimer Outperform → Perform
2023-08-07 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-08-07 Herabstufung Stifel Buy → Hold
2023-08-07 Herabstufung Wedbush Outperform → Neutral
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-03-13 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-01-03 Herabstufung Guggenheim Buy → Neutral
2022-11-01 Eingeleitet Loop Capital Hold
2022-03-31 Eingeleitet Berenberg Hold
2021-11-02 Hochstufung Guggenheim Neutral → Buy
2021-10-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-10-07 Herabstufung Jefferies Buy → Hold
2021-09-23 Eingeleitet Needham Buy
2021-06-16 Herabstufung Citigroup Buy → Neutral
2021-04-07 Eingeleitet Piper Sandler Overweight
2021-02-26 Herabstufung Mizuho Buy → Neutral
2021-02-25 Bestätigt H.C. Wainwright Neutral
2021-02-02 Fortgesetzt Raymond James Mkt Perform
2021-01-22 Herabstufung BMO Capital Markets Outperform → Market Perform
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2021-01-04 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-12-04 Hochstufung Mizuho Neutral → Buy
2020-12-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-11-16 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-11-06 Bestätigt H.C. Wainwright Neutral
2020-09-11 Hochstufung Wedbush Neutral → Outperform
2020-08-10 Hochstufung Raymond James Mkt Perform → Outperform
2020-05-08 Herabstufung Wedbush Outperform → Neutral
2020-04-08 Herabstufung Guggenheim Buy → Neutral
2020-03-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-03-06 Eingeleitet Citigroup Buy
2020-02-28 Bestätigt H.C. Wainwright Neutral
2020-02-06 Eingeleitet Mizuho Neutral
2019-12-06 Bestätigt RBC Capital Mkts Outperform
2019-12-05 Bestätigt Guggenheim Buy
2019-12-05 Herabstufung SunTrust Buy → Hold
2019-10-30 Eingeleitet H.C. Wainwright Neutral
2019-05-23 Eingeleitet Wedbush Outperform
2019-04-25 Eingeleitet Jefferies Buy
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-10-11 Eingeleitet Oppenheimer Outperform
Alle ansehen

Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten

pulisher
Jun 18, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025

Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):